Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer

Abstract

ObjectiveWe investigated the clinical significance of preoperative pan-immune-inflammation value (PIV) in patients with colorectal cancer (CRC).MethodsIn this retrospective study, 366 cases who underwent surgery for CRC were enrolled. Their clinical data were collected. PIV was calculated with the formula PIV = [neutrophil count (109/L)× platelet count (109/L) × monocyte count (109/L) /lymphocyte count (109/L). Patients were divided into high PIV (> median PIV) and low PIV (< median PIV) groups. The relationship between PIV and clinicopathological features of CRC was investigated. Receiver operating characteristic (ROC) curve was plotted to indicate the value of immune-inflammatory biomarkers (IIBs) in predicting the TNM stage of CRC, and the area under the curve (AUC) was calculated to evaluate the actual clinical value of IIBs. AUC > 0.5 and closer to 1 indicated the better predictive efficacy. The influencing factors of PIV in CRC were analyzed.ResultsWe found that PIV was positively correlated with tumor size (r = 0.300, p < 0.05), carcinoembryonic antigen (CEA) (r = 0.214, p < 0.05) and carbohydrate antigen 125 (CA-125) (r = 0.249, p < 0.05), but negatively correlated with albumin (Alb) (r = −0.242, p < 0.05). PIV was significantly different in patients with different tumor locations (left or right), surgical methods (laparotomy versus laparoscopic surgery) (p < 0.05), and patients with different pathological T stages, N-stage and TNM stages (p < 0.05). ROC curve analysis of IIBs showed the AUC of PIV was greater than other markers when combined with CEA or carbohydrate antigen 19–9 (CA19–9). Multivariate regression analysis identified T stage, CEA, Alb, and tumor size as the independent influential factors of PIV in CRC.ConclusionPIV is associated with the tumor stage in patients with CRC, which may be useful in preoperative assessment of CRC.

Influence of systemic inflammatory indices on hospital stay and dialysis post-earthquake: A clinical study

“…(Exp(B): 1.261, p= 0.038) The relevance of systemic inflammatory markers goes beyond trauma. PIV has emerged as significant indicators in predicting adverse clinical outcomes following malignancy [ 21 , 22 ]. Malignancy is known to incite systemic inflammatory responses, with cascading effects on the body’s immune and clotting systems.…”

The role of new inflammatory markers in determining disease activation and severity in patients with hidradenitis suppurativa

“…[8][9][10][11] Pan-immune-inflammation value (PIV), an inflammation marker that has been cited in recent literature, has been investigated in some cancer types; there is only one study investigating its role in HS. [12][13][14] The systemic immune-inflammatory index (SIII) and monocyte/lymphocyte ratio (MLR) have also been investigated as promising inflammatory markers; however, data on these parameters in HS patients are limited.…”

“…Neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and platelet/neutrophil ratio (PNR) have been investigated as potential diagnostic and prognostic markers in chronic inflammatory diseases, such as psoriasis and some cancers 8–11 . Pan‐immune‐inflammation value (PIV), an inflammation marker that has been cited in recent literature, has been investigated in some cancer types; there is only one study investigating its role in HS 12–14 . The systemic immune‐inflammatory index (SIII) and monocyte/lymphocyte ratio (MLR) have also been investigated as promising inflammatory markers; however, data on these parameters in HS patients are limited.…”